Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS). Nachtkamp K, Schulz F, Kasprzak A, Strupp C, et al. Ann Hematol 2025;104:3251-3259.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nachtkamp K, Schulz F, Kasprzak A, Strupp C, et al. Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS). Ann Hematol 2025;104:3251-3259.
PMID: 40488753